Lipofen Capsule
NDC Package 62559-306-90
Package Information
Lipofen (fenofibrate) capsules is lIPOFEN is indicated as adjunctive therapy to diet:to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL).to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. This formulation utilizes a capsule delivery system. Marketed by Ani Pharmaceuticals, Inc., this product is identified by NDC 62559-306 and is authorized under FDA application NDA021612.
Identification & Billing
- RxCUI: 616852 - fenofibrate 150 MG Oral Capsule
- RxCUI: 616853 - fenofibrate 50 MG Oral Capsule
- RxCUI: 702055 - Lipofen 150 MG Oral Capsule
- RxCUI: 702055 - fenofibrate 150 MG Oral Capsule [Lipofen]
- RxCUI: 702169 - Lipofen 50 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 62559 - Ani Pharmaceuticals, Inc.
- 62559-306 - Lipofen
- 62559-306-90 - 90 CAPSULE in 1 BOTTLE
- 62559-306 - Lipofen
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62559-306-90 identifies a specific commercial package of 90 capsule in 1 bottle of Lipofen, a human prescription drug labeled by Ani Pharmaceuticals, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 90 billable units per package. This capsule is formulated for oral use and contains fenofibrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ani Pharmaceuticals, Inc. on September 24, 2021. The current certification is valid through December 31, 2027.
How is this Ani Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62559030690. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.